Speakers

Amine Sadok

Director, Head of Biology

Monte Rosa Therapeutics

Benika Pinch

Principal Scientist

Novartis Institutes for BioMedical Research

David Wang

VP Business Development

Kangpu Biopharmaceuticals

Kevin Moreau

Associate Director

PROTAC Safety Science AstraZeneca

Catherine Lindon

Associate Professor

University of Cambridge, Department of Pharmacology

Felix Hausch

Professor

Technical University Darmstadt

Mikael Altun

Associate Professor

Karolinska Institute

Vaishali Dixit

Director, DMPK

Kymera Therapeutics

Argyrides Argyrou

Associate Principal Scientist

AstraZeneca

Max Cynader

CEO & Co-Founder

Primary Peptides

Robin Ketteler

Professor

University College London

Sandra Stefanovic-Barrett

Senior Research Associate

AstraZeneca

Benedict Cross

CTO

PhoreMost

Boxun Lu

Professor

Fudan University

Ingo Hartung

Director

Merck KGaA

Rob Sellar

CRUK Advanced Clinician Scientist, Honorary Consultant Haematologist

UCL Cancer Institute

Jack Jin

COO

Primary Peptides

Matthias Brand

VP Biology

Proxygen

Michal J. Walczak

CSO

Captor Therapeutics

Oskar Hoff

Head of Medicinal Chemistry

Celeris Therapeutics

Bernd Boidol

CEO

Proxygen

Maria Górna

Principle Investigator, Structural Biology Group

University of Warsaw

Matthew Trotter

Vice President, Predictive Sciences

Bristol Myers Squibb

Tim Clausen

Senior Scientist

Research Institute Of Molecular Pathology

Adam Bond PhD

Student Centre for Targeted Protein Degradation (CeTPD)

University of Dundee

Cornelia Wilson

Senior Lecturer and Academic Laboratory Director

Canterbury Christ Church University

Paola Martinelli

Principal Scientist

Boehringer Ingelheim

Silke Buschbom-Helmke

Senior Scientist

Boehringer Ingelheim

Agnieszka Konopacka

In Vitro Biologist

GlaxoSmithKline

Dennis Gillingham

Associate Professor

University of Basel

Ian Churcher

CSO

Amphista Therapeutics

Jeffrey Simard

Associate Director, Cell Pharmacology

C4 Therapeutics